Advanced visualization software firm Imaging Biometrics is highlighting research that shows the efficacy of using MRI to monitor high-grade glioma treatment response.
The review was published March 3 in Frontiers in Oncology and was authored by a team from the European Cooperation in Science and Technology (COST) Glioma MR Imaging 2.0 (GLiMR) Initiative. The study authors found that dynamic susceptibility contrast MRI is an effective way to monitor high-grade brain tumors.
Imaging Biometrics' software modules, IB Neuro and IB DCE, were used in the research, the company said.
